Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin™) in cancer patients

Oncology Reports

Volumn 12, Issue 3, 2004, Pages 581-585

  Maeda, Yorinobu ^a   Ohune, Terumasa ^a   Nakamura, Mamoru ^a   Yamasaki, Miho ^a   Kiribayashi, Yoshie ^a   Murakami, Teruo ^b  

^a Chugoku Rousai Hospital   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Diarrhoea; Irinotechan; Kremezin; Oral adsorbent

Indexed keywords

ANTIDIARRHEAL AGENT; ANTINEOPLASTIC AGENT; AST 120; CAMPTOTHECIN; CARBON; DRUG DERIVATIVE; IRINOTECAN; MICROSPHERE; OXIDE;

ADSORPTION; ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DEFECATION; DIARRHEA; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; NEOPLASM; TIME; TREATMENT OUTCOME;

ADSORPTION; ADULT; AGED; ANTIDIARRHEALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBON; DEFECATION; DIARRHEA; FEMALE; HUMANS; MALE; MICROSPHERES; MIDDLE AGED; NEOPLASMS; OXIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 7744219685     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.3.581     Document Type: Article

References (14)

1. Creemers GJ, Lund B and Verweij J: Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 20: 73-96, 1994.
2. Kaneda N and Yokokura T: Non-linear pharmacokinetics of CPT-11 in rats. Cancer Res 50: 1721-1725, 1990.
3. Kehrer DFS, Sparreboom A, Verweij J, Bruijn P, Nierop CA, Schraaf J, Ruijgrok EJ and Jonge MJA: Modulation of irinotecan-induced diarrhoea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7: 1136-1141, 2001. (Pubitemid 32708662)
4. Takeda Y, Kobayashi K, Akiyama Y, Soma T, Honda S, Kudoh S and Kudo K: Prevention of irinotecan (CPT-11)-induced diarrhoea by oral alkalization combined with control ofin cancer patients. Int J Cancer 92: 269-275, 2001. (Pubitemid 32225380)
5. Chester JD, Joel SP, Cheeseman SL, Hall GD, Braun MS, Perry J, Davis T, Button CJ and Seymour MT: Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. J Clin Oncol 21: 1125-1132, 2003. (Pubitemid 46594143)
6. Kobayashi K: Chemotherapy-induced diarrhea. Gan To Kagaku Ryoho 30: 765-771, 2003.
7. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE and Ratain MJ: Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhoea. Cancer Res 15: 3723-3725, 1994. (Pubitemid 24241187)
8. Mick R, Gupta E, Vokes EE and Ratain MJ: Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 14: 2012-2019, 1996. (Pubitemid 26230101)
9. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T and Kamataki T: Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56: 3752-3757, 1996. (Pubitemid 26272025)
10. Niwa T, Miyazaki T, Tsukushi S, Maeda K, Tsubakihara Y, Owada A and Shiigal T: Accumulation of indoxyl-beta-D-glucuronide in uremic serum: suppression of its production by oral sorbent and efficient removal by hemodialysis. Nephron 74: 72-78, 1996. (Pubitemid 26300652)
11. Toyota T, Kitamura Y, Araki H, Sadakane N, Futagami K, Furuno K and Gomita Y: Influence of oral adsorbent AST-120 on anticonvulsive effect of zonisamide in rats. Pharmacol Biochem Behav 70: 375-379, 2001. (Pubitemid 33049949)
12. Kurita A and Kaneda N: High-performance liquid chromatographic method for the simultaneous determination of the camtothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. J Chromatogr B Biomed Sci 724: 335-344, 1991.
13. Horikawa M, Kato Y and Sugiyama Y: Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm Res 19: 1345-1353, 2002.
14. Balram C, Zhou QY, Cheung YB and Lee EJ: Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats. Drug Metabol Drag Interact 19: 137-148, 2002. (Pubitemid 36537999)